Intrexon Corporation (XON) Hits New 1-Year Low at $15.57
Shares of Intrexon Corporation (NYSE:XON) hit a new 52-week low during trading on Tuesday . The stock traded as low as $15.57 and last traded at $15.54, with a volume of 528985 shares changing hands. The stock had previously closed at $15.94.
Several brokerages recently commented on XON. Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a report on Monday, August 7th. BidaskClub lowered Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. JMP Securities reissued an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research note on Thursday, October 5th. Finally, Griffin Securities reissued a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $43.20.
The company has a quick ratio of 2.25, a current ratio of 2.45 and a debt-to-equity ratio of 0.01.
Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The firm had revenue of $54.40 million for the quarter, compared to analyst estimates of $57.17 million. During the same period in the previous year, the firm earned ($0.42) earnings per share. The company’s revenue was up 3.6% compared to the same quarter last year. equities analysts expect that Intrexon Corporation will post -0.84 earnings per share for the current fiscal year.
In other news, CEO Randal J. Kirk bought 132,625 shares of the stock in a transaction dated Friday, August 11th. The shares were bought at an average cost of $18.85 per share, with a total value of $2,499,981.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert B. Shapiro bought 2,850 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The disclosure for this purchase can be found here. Insiders have bought 144,569 shares of company stock worth $2,719,429 over the last ninety days. 56.30% of the stock is owned by insiders.
Several large investors have recently modified their holdings of XON. UBS Asset Management Americas Inc. raised its position in shares of Intrexon Corporation by 16.7% during the first quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 4,773 shares during the period. SG Americas Securities LLC bought a new stake in Intrexon Corporation during the first quarter worth $164,000. Teachers Advisors LLC grew its holdings in Intrexon Corporation by 6.8% during the first quarter. Teachers Advisors LLC now owns 53,606 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 3,434 shares in the last quarter. Legal & General Group Plc grew its holdings in Intrexon Corporation by 102.5% during the first quarter. Legal & General Group Plc now owns 18,450 shares of the biotechnology company’s stock worth $365,000 after buying an additional 9,340 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Intrexon Corporation by 5.6% during the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock worth $84,954,000 after buying an additional 226,090 shares in the last quarter. 82.10% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/intrexon-corporation-xon-hits-new-1-year-low-at-15-57/1686476.html.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.